Back to News
Market Impact: 0.25
Satellos Completes Enrollment In Phase 2 Forazapadin Trial For DMD
Source: Nasdaq
Healthcare & Biotech
Satellos Bioscience completed enrollment in BASECAMP, its Phase 2 trial of forazapadin for Duchenne muscular dystrophy. The study is evaluating the treatment in ambulatory boys aged 7 to 10 years, advancing the company toward forthcoming clinical data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- PHC Holdings surge to near 4-year high after Toho takeover proposal confirmed
- Communiqué de presse : Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée
- Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Why is Toho stock volatile today?